IPHA

Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update

Retrieved on: 
화요일, 5월 7, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Webcast, IPHA, EDT, Telephone, IPH, Euronext Paris

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tuesday, May 14, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2024.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tuesday, May 14, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2024.
  • Participants during the call will be:
    The live webcast will be available at the following link:
    Participants may also join via telephone using the following registration link: https://registrations.events/direct/Q4I9730892
    This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com .
  • A replay of the webcast will be available on the Company website for 90 days following the event.

Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Retrieved on: 
월요일, 4월 15, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cancer, Safety, Hematology, IPHA, Research, AML, IPH, Euronext Paris, Fast track (FDA), Acute lymphoblastic leukemia, Patient, Society, Bone marrow, Syndrome, Acute myeloid leukemia, Clinical trial, Pharmaceutical industry

SAR443579 is an investigational trifunctional anti-CD123 NKp46xCD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi.

Key Points: 
  • SAR443579 is an investigational trifunctional anti-CD123 NKp46xCD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi.
  • SAR443579 received FDA Fast Track Designation for the treatment of acute myeloid leukemia.
  • “The progression of SAR443579 to the Phase 2 expansion part of the clinical trial in blood cancers is another step in bringing this innovative NK cell engager to patients,” said Dr. Sonia Quaratino, Chief Medical Officer of Innate Pharma.
  • “SAR443579 has shown promising clinical efficacy in the dose escalation of the Phase 1/2 in R/R AML patients, and we look forward to the dose expansion part of the study."

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024

Retrieved on: 
월요일, 4월 15, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Annual, IPHA, IPH, AGM, Euronext Paris, Code, Security (finance)

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will hold its Annual General Meeting of Shareholders (“AGM”) at 10:30 a.m. CEST on May 23, 2024 in its headquarters, 117 avenue de Luminy, F-13009 Marseille.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will hold its Annual General Meeting of Shareholders (“AGM”) at 10:30 a.m. CEST on May 23, 2024 in its headquarters, 117 avenue de Luminy, F-13009 Marseille.
  • The Notice of Meeting of this AGM was published on April 15, 2024 in the French legal bulletin.
  • The Annual General Meeting will also be broadcasted live and available at the following link: https://app.livestorm.co/p/6ae4e3e6-227c-465b-a057-88d52b2209a1
    A guided tour of the Company's laboratories is organized on the same day at 9:30 a.m. CEST for shareholders.
  • Shareholders holding “au porteur” (bearer) shares will need to obtain an “attestation de participation” (certificate of shareholding) from their brokers.

Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Retrieved on: 
수요일, 4월 10, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Drug, Carcinoma, IPHA, Doctor of Philosophy, PDX, IPH, Euronext Paris, EV, ADC, DVM, Patient, Therapeutic index, AACR, Cancer, Vaccine

In preclinical studies, data demonstrated that IPH45 effectively inhibits Nectin-4 expressing tumor growth both in vitro and in vivo, including in Enfortumab Vedotin (EV) refractory models.

Key Points: 
  • In preclinical studies, data demonstrated that IPH45 effectively inhibits Nectin-4 expressing tumor growth both in vitro and in vivo, including in Enfortumab Vedotin (EV) refractory models.
  • Importantly, IPH45 shows stronger activity than EV, in multiple urothelial carcinoma PDX (patient-derived xenografted) mice models, across Nectin-4high and Nectin-4low expression levels.
  • “IPH45 is a novel and differentiated Nectin-4 ADC with preclinical efficacy in tumor types with various expression levels of Nectin-4.
  • Its exatecan payload allow for higher bystander-effect and a broader therapeutic index than MMAE-ADCs," commented Prof. Eric Vivier, DVM, PhD, Chief Scientific Officer at Innate Pharma.

Innate Pharma Announces Its Participation in Upcoming Investor Conference

Retrieved on: 
화요일, 4월 9, 2024
Communications, Health, General Health, Pharmaceutical, Public Relations, Investor Relations, Biotechnology, Euronext Paris, IPHA, IPH

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below.

Key Points: 

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below.

Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F

Retrieved on: 
금요일, 4월 5, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Euronext Paris, Document, IPHA, IPH, Annual report

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2023 Universal Registration Document (Document d’enregistrement universel) for the year ending December 31, 2023 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 4, 2024.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2023 Universal Registration Document (Document d’enregistrement universel) for the year ending December 31, 2023 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 4, 2024.
  • It can be downloaded (in French) on the Company’s website and on the AMF’s website .
  • The Company also announced today the filing of its annual report on Form 20-F for the year ending December 31, 2023 with the United States Securities and Exchange Commission (“SEC”).
  • It can be also be accessed on the Company’s website and on the SEC’s website .

Innate Pharma Announces Its Participation to Upcoming Investor Conference

Retrieved on: 
화요일, 3월 19, 2024
Professional Services, Health, Finance, Research, Science, Pharmaceutical, Biotechnology, Euronext Paris, IPHA, IPH

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below.
  • Participants will be Sonia Quaratino, Executive Vice President, Chief Medical Officer, Yannis Morel, Executive Vice President, Chief Operating Officer and Arvind Sood, Executive Vice President, President of US Operations.

Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results

Retrieved on: 
목요일, 3월 14, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Euronext Paris, Telephone, Webcast, IPHA, IPH, EDT

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, March 21, 2024 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2023.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, March 21, 2024 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2023.
  • Participants during the call will be:
    The live webcast will be available at the following link:
    Participants may also join via telephone using the following registration link: https://registrations.events/direct/Q4I409542
    This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com .
  • A replay of the webcast will be available on the Company website for 90 days following the event.

Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma

Retrieved on: 
수요일, 3월 6, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, CD20, IPH, CD16, NHL, NCR1, Relapse, IPHA, Safety, Therapy, Patient, NK, Euronext Paris, Pharmaceutical industry

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its Phase 1/2 multicenter trial ( NCT06088654 ), investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma (NHL).

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its Phase 1/2 multicenter trial ( NCT06088654 ), investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma (NHL).
  • The study is planned to enroll up to 184 patients.
  • “We are pleased to announce the dosing of a first patient in this Phase 1/2 study evaluating IPH6501, our proprietary ANKET® asset and the first tetraspecific NK Cell Engager to enter the clinic.” commented Dr Sonia Quaratino, Chief Medical Officer at Innate Pharma.
  • In this context, IPH6501 represents an innovative option for the treatment of patients with R/R B-cell non-Hodgkin’s lymphomas and has the potential to fulfil a large unmet need.”

Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024

Retrieved on: 
수요일, 3월 6, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Euronext Paris, IPH, Neoplasm, Engineering, Doctor of Philosophy, AACR, IPHA, DVM, ADC

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding its preclinical asset IPH45, a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding its preclinical asset IPH45, a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.
  • "We are excited to present our findings on IPH45 at this year's AACR.
  • Our studies demonstrate that IPH45 effectively inhibits tumor growth both in vitro and in vivo, and it exhibits a favorable safety profile in preclinical studies," stated Prof. Eric Vivier, DVM, PhD, Chief Scientific Officer at Innate Pharma.
  • "These promising results underscore the potential of IPH45 and reflect our dedication to pioneering the next wave of cancer treatments through advanced antibody engineering.